

References

S-109

1. Hur S, Chung JW, Kim HC, et al. Survival outcomes and prognostic factors of transcatheter arterial chemoembolization for hepatic neuroendocrine metastases. *J Vasc Interv Radiol*. 2013; 24(7):947-956.
2. Zhou Y, Zhang X, Wu L, et al. Meta-analysis: preoperative transcatheter arterial chemoembolization does not improve prognosis of patient with resectable hepatocellular carcinoma. *BMC Gastroenterol*. 2013;13(1):51.
3. Song Y, Shin S, Cho S, et al. Transarterial chemoembolization as first-line therapy for hepatocellular carcinomas infeasible for ultrasound-guided radiofrequency ablation: a retrospective cohort study of 116 patients. *Acta Radiol*. 2015;56(1):70-7.
4. Venook A. Nonsurgical local treatment strategies for colorectal cancer liver metastases. UpToDate. Waltham, Mass. UpToDate; 2015.
5. Paul S, Sharma H. Role of transcatheter intra-arterial therapies for hepatocellular carcinoma. *J Clin Exp Hepatol*. 2014;(3):112-121.
6. Yi-Xiang Y, Baere T, Idee JM, et al. Transcatheter embolization therapy in liver cancer: an update of clinical evidences. *Chin J Cancer Res*. 2015;27(2):96-121.
7. Lan T, Chang L, Rahmathullah MN, et al. Comparative efficacy of interventional therapies for early-stage hepatocellular carcinoma: a PRISMA-compliant systemic review and network meta-analysis. *Medicine (Baltimore)*. 2016;95(15):e3185.
8. Varghese J, Kedarisetty C, Venkataraman J, et al. Combination of TACE and sorafenib improves outcomes of BCLC stages B/C of hepatocellular carcinoma: a single centre experience. *Ann Hepatol*. 2017;16(2):247-254.
9. Kim J, Sinn D, Shin S, et al. The role of scheduled second TACE in early-stage hepatocellular carcinoma with complete response to initial TACE. *Clin Mole Hepatol*. 2017;23:42-50.
10. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology Hepatobiliary cancer. Version 2.2019 Accessed July 1, 2019.
11. Nigri G, Petrucciani N, Debs T, et al. Treatment options for PNET liver metastases: a systematic review. *World Journal of Surgical Oncology*. 2018;16(1):N.PAG.
12. National Cancer Institute, Surveillance Epidemiology and End Results Program. Cancer Stat Facts: Liver and Intrahepatic Bile Duct Cancer. n.d.; <https://seer.cancer.gov/statfacts/html/livibd.html>. Accessed July 6, 2018.
13. Qi X, Wang D, Su C, et al. Hepatic resection versus transarterial chemoembolization for the initial treatment of hepatocellular carcinoma: A systematic review and meta-analysis. *Oncotarget*. Jul 30 2015;6(21):18715-18733. PMID 26243835
14. Tian X, Dai Y, Wang DQ, et al. Transarterial chemoembolization versus hepatic resection in hepatocellular carcinoma treatment: a meta-analysis. *Drug Des Devel Ther*. Aug 2015;9:4431-4440. PMID 26309396

15. Bush DA, Smith JC, Slater JD, et al. Randomized clinical trial comparing proton beam radiation therapy with transarterial chemoembolization for hepatocellular carcinoma: results of an interim analysis. *Int J Radiat Oncol Biol Phys*. May 1 2016;95(1):477-482. PMID 27084661
16. Biederman DM, Titano JJ, Korff RA, et al. Radiation segmentectomy versus selective chemoembolization in the treatment of early-stage hepatocellular carcinoma. *J Vasc Interv Radiol*. Jan 2018;29(1):30-37 e32. PMID 29169782
17. Si T, Chen Y, Ma D, et al. Preoperative transarterial chemoembolization for resectable hepatocellular carcinoma in Asia area: a meta-analysis of random controlled trials. *Scand J Gastroenterol*. Dec 2016;51(12):1512-1519. PMID 27598831
18. Yeh ML, Huang CI, Huang CF, et al. Neoadjuvant transcatheter arterial chemoembolization does not provide survival benefit compared to curative therapy alone in single hepatocellular carcinoma. *Kaohsiung J Med Sci*. Feb 2015;31(2):77-82. PMID 25645985
19. Liao M, Zhu Z, Wang H, et al. Adjuvant transarterial chemoembolization for patients after curative resection of hepatocellular carcinoma: a meta-analysis. *Scand J Gastroenterol*. Jun - Jul 2017;52(6-7):624-634. PMID 28276833
20. Liu H, Wang ZG, Fu SY, et al. Randomized clinical trial of chemoembolization plus radiofrequency ablation versus partial hepatectomy for hepatocellular carcinoma within the Milan criteria. *Br J Surg*. Mar 2016;103(4):348-356. PMID 26780107
21. Ako S, Nakamura S, Nouse K, et al. Transcatheter arterial chemoembolization to reduce size of hepatocellular carcinoma before radiofrequency ablation. *Acta Med Okayama*. Feb 2018;72(1):47-52. PMID 29463938
22. Haochen W, Jian W, Li S, et al. Transarterial chemoembolization plus multi-imaging-guided radiofrequency ablation for elimination of hepatocellular carcinoma nodules measuring 3.1 to 5.0 cm: a single-center study. *J Int Med Res*. Jan 1 2018:300060518768420. PMID 29683022
23. Bholee AK, Peng K, Zhou Z, et al. Radiofrequency ablation combined with transarterial chemoembolization versus hepatectomy for patients with hepatocellular carcinoma within Milan criteria: a retrospective case-control study. *Clin Transl Oncol*. Jul 2017;19(7):844-852. PMID 28070766
24. Li L, Tian J, Liu P, et al. Transarterial chemoembolization combination therapy vs monotherapy in unresectable hepatocellular carcinoma: a meta-analysis. *Tumori*. Jun 02 2016;2016(3):301-310. PMID 27002950
25. Wang X, Hu Y, Ren M, et al. Efficacy and safety of radiofrequency ablation combined with transcatheter arterial chemoembolization for hepatocellular carcinomas compared with radiofrequency ablation alone: a time-to-event meta-analysis. *Korean J Radiol*. Jan-Feb 2016;17(1):93-102. PMID 26798221
26. Yi Y, Zhang Y, Wei Q, et al. Radiofrequency ablation or microwave ablation combined with transcatheter arterial chemoembolization in treatment of hepatocellular carcinoma by comparing with radiofrequency ablation alone. *Chin J Cancer Res*. Feb 2014;26(1):112-118. PMID 24653633
27. Peng ZW, Zhang YJ, Chen MS, et al. Radiofrequency ablation with or without transcatheter arterial chemoembolization in the treatment of hepatocellular carcinoma: a prospective randomized trial. *J Clin Oncol*. Feb 01 2013;31(4):426-432. PMID 23269991

28. Organ Procurement and Transplantation Network (OPTN). Organ Distribution: Allocation of Livers. 2013. http://optn.transplant.hrsa.gov/PoliciesandBylaws2/policies/pdfs/policy_8.pdf. Accessed July 20, 2015.
29. Organ Procurement and Transplantation Network (OPTN). OPTN Policies. 2018; https://optn.transplant.hrsa.gov/media/1200/optn_policies.pdf#nameddest=Policy_09. Accessed July 19, 2018.
30. Si T, Chen Y, Ma D, et al. Transarterial chemoembolization prior to liver transplantation for patients with hepatocellular carcinoma: A meta-analysis. *J Gastroenterol Hepatol*. Jul 2017;32(7):1286-1294. PMID 28085213
31. Gabr A, Abouchaleh N, Ali R, et al. Comparative study of post-transplant outcomes in hepatocellular carcinoma patients treated with chemoembolization or radioembolization. *Eur J Radiol*. Aug 2017;93:100-106. PMID 28668402
32. Boehm LM, Jayakrishnan TT, Miura JT, et al. Comparative effectiveness of hepatic artery based therapies for unresectable intrahepatic cholangiocarcinoma. *J Surg Oncol*. Feb 2015;111(2):213-220. PMID 25176325
33. Knppel M, Kubicka S, Vogel A, et al. Combination of conservative and interventional therapy strategies for intra- and extrahepatic cholangiocellular carcinoma: a retrospective survival analysis. *Gastroenterol Res Pract*. Jul 2012;2012:190708. PMID 21776251
34. Zacharias AJ, Jayakrishnan TT, Rajeev R, et al. Comparative effectiveness of hepatic artery based therapies for unresectable colorectal liver metastases: a meta-analysis. *PLoS One*. Oct 2015;10(10):e0139940. PMID 26448327
35. Richardson AJ, Laurence JM, Lam VW. Transarterial chemoembolization with irinotecan beads in the treatment of colorectal liver metastases: systematic review. *J Vasc Interv Radiol*. Aug 2013;24(8):1209-1217. PMID 23885916
36. Riemsma RP, Bala MM, Wolff R, et al. Percutaneous ethanol injection for liver metastases. *Cochrane Database Syst Rev*. May 31 2013(5):CD008717. PMID 23728679
37. Martin RC, 2nd, Scoggins CR, Schreeder M, et al. Randomized controlled trial of irinotecan drug-eluting beads with simultaneous FOLFOX and bevacizumab for patients with unresectable colorectal liver-limited metastasis. *Cancer*. Oct 15 2015;121(20):3649-3658. PMID 26149602
38. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Neuroendocrine and Adrenal Tumors, Version 1.2019. Updated March 5, 2019. https://www.nccn.org/professionals/physician_gls/pdf/neuroendocrine.pdf. Accessed May 28, 2019.
39. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Breast Cancer, Version 1.2019. Updated March 14, 2019. https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf. Accessed May 28, 2019.